Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells

The ability of an α-emitter conjugated to a chimaeric anti-CD20 monoclonal antibody to kill selectively human B-lymphoma cells in vitro is reported. Two B-lymphoma cell lines RAEL and K422, and normal haematopoietic progenitor cells from human bone marrow aspirates were incubated with(211)At-rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Aurlien, E, Larsen, R H, Kvalheim, G, Bruland, Ø S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408791/
https://www.ncbi.nlm.nih.gov/pubmed/11044364
http://dx.doi.org/10.1054/bjoc.2000.1453
_version_ 1782155707847540736
author Aurlien, E
Larsen, R H
Kvalheim, G
Bruland, Ø S
author_facet Aurlien, E
Larsen, R H
Kvalheim, G
Bruland, Ø S
author_sort Aurlien, E
collection PubMed
description The ability of an α-emitter conjugated to a chimaeric anti-CD20 monoclonal antibody to kill selectively human B-lymphoma cells in vitro is reported. Two B-lymphoma cell lines RAEL and K422, and normal haematopoietic progenitor cells from human bone marrow aspirates were incubated with(211)At-rituximab (Rituxan® or MabThera™) and plated in clonogenic assays for survival analyses. Following 1 h incubation with(211)At-rituximab, in concentrations which gave an initial activity of 50 kBq ml(–1), a high tumour cell to normal bone marrow cell toxicity ratio was obtained; 4.1 to 1.0 log cell kill. Biodistribution studies of(211)At-rituximab in Balb/c mice showed similar stability as that of the iodinated analogue. The data indicate that testing of(211)At-rituximab in human patients is warranted. © 2000 Cancer Research Campaign
format Text
id pubmed-2408791
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24087912009-09-10 Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells Aurlien, E Larsen, R H Kvalheim, G Bruland, Ø S Br J Cancer Regular Article The ability of an α-emitter conjugated to a chimaeric anti-CD20 monoclonal antibody to kill selectively human B-lymphoma cells in vitro is reported. Two B-lymphoma cell lines RAEL and K422, and normal haematopoietic progenitor cells from human bone marrow aspirates were incubated with(211)At-rituximab (Rituxan® or MabThera™) and plated in clonogenic assays for survival analyses. Following 1 h incubation with(211)At-rituximab, in concentrations which gave an initial activity of 50 kBq ml(–1), a high tumour cell to normal bone marrow cell toxicity ratio was obtained; 4.1 to 1.0 log cell kill. Biodistribution studies of(211)At-rituximab in Balb/c mice showed similar stability as that of the iodinated analogue. The data indicate that testing of(211)At-rituximab in human patients is warranted. © 2000 Cancer Research Campaign Nature Publishing Group 2000-11 2000-10-26 /pmc/articles/PMC2408791/ /pubmed/11044364 http://dx.doi.org/10.1054/bjoc.2000.1453 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Aurlien, E
Larsen, R H
Kvalheim, G
Bruland, Ø S
Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
title Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
title_full Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
title_fullStr Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
title_full_unstemmed Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
title_short Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
title_sort demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)at-rituximab against non-hodgkin's lymphoma cells
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408791/
https://www.ncbi.nlm.nih.gov/pubmed/11044364
http://dx.doi.org/10.1054/bjoc.2000.1453
work_keys_str_mv AT aurliene demonstrationofhighlyspecifictoxicityoftheaemittingradioimmunoconjugate211atrituximabagainstnonhodgkinslymphomacells
AT larsenrh demonstrationofhighlyspecifictoxicityoftheaemittingradioimmunoconjugate211atrituximabagainstnonhodgkinslymphomacells
AT kvalheimg demonstrationofhighlyspecifictoxicityoftheaemittingradioimmunoconjugate211atrituximabagainstnonhodgkinslymphomacells
AT brulandøs demonstrationofhighlyspecifictoxicityoftheaemittingradioimmunoconjugate211atrituximabagainstnonhodgkinslymphomacells

Ejemplares similares